Zenocutuzumab, a bispecific antibody, is indicated for non-small-cell lung cancer and pancreatic adenocarcinoma with NRG1 ...
The systemic agent is the first approved by the FDA for patients with NSCLC or pancreatic adenocarcinoma harboring an NRG1 gene fusion.